Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis
Sign Up to like & getrecommendations! Published in 2021 at "Kidney International Reports"
DOI: 10.1016/j.ekir.2021.07.015
Abstract: Introduction Molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor for renal anemia treatment, was evaluated in 5 phase 3 studies (MIYABI program). We report the results of the MIYABI hemodialysis-maintenance study. Methods This 52-week, randomized, double-blinded,… read more here.
Keywords: receiving dialysis; japanese patients; molidustat; molidustat darbepoetin ... See more keywords
Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial.
Sign Up to like & getrecommendations! Published in 2021 at "American journal of nephrology"
DOI: 10.1159/000518071
Abstract: INTRODUCTION Molidustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that predominantly induces renal production of erythropoietin (EPO). Molidustat was evaluated for the treatment of anemia associated with chronic kidney disease (CKD) in the "Molidustat… read more here.
Keywords: anemia; treatment; efficacy; molidustat ... See more keywords